This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the “Group”) or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice. Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated.

All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto.

The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations, plans and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those possibly described in the respective disclosures. Should one or more of these or other risks, uncertainties or factors (e.g. events of force majeure, including but not limited to unrest, acts of war, pandemics or acts of God) materialize, plans change or should underlying expectations not occur or assumptions prove incorrect, Siemens Healthineers’ management actions, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the forward-looking statement.

This document includes supplemental financial measures that are or may be alternative performance measures not precisely defined in the applicable financial reporting framework (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, and therefore they may not be comparable to those included in this document.

Please find further explanations regarding our (supplemental) financial measures in chapter “A.2 Financial performance system” and in the Notes to consolidated financial statements, Note 29 “Segment information” of the Annual Report 2022 of Siemens Healthineers. Additional information is also included in the Quarterly Statement and in the Half-Year Financial Report 2023. These documents can be found under the following internet link https://www.siemens-healthineers.com/investor-relations/presentations-financial-publications .

Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements. This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version.

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

In the event that the male form is used in this document, the information nevertheless refers to all persons (male, female, non-binary).
Q4 and FY 2023
Q4 – Strong finish...

1.16  Equipment book-to-bill

11%  Comparable revenue growth  
(Ex antigen)

16%  Adjusted EBIT growth  
(Ex antigen)

>€0.5bn  Free cash flow
Continued strong performance
- Excellent revenue growth of 11% at industry-leading margins
- Further growing order book

Transformation on track
- Continued revenue growth (ex antigen) and margin again positive
- Transformation savings kicking in as planned

Very strong finish
- Revenue growth of 30% and margin of 19%
- Further growing order book with equipment book-to-bill >1.2

Robust finish
- Continued growth and strong margin
- Further growing order book
Delivering on “New Ambition”

Key achievements in FY2023

- **Leading innovations** introduced to market in all segments
- **Taking decisive actions**: Diagnostics transformation program, refocusing Endovascular Robotics, diligent execution of pricing measures
- **Winning Value Partnerships of >€2bn** from a unique market position
- **Further expanding backlog** with equipment book-to-bill of 1.15
- Imaging, Varian, Advanced Therapies **gaining further market share**
- **Outstanding growth of 8%** (ex-antigen)
- **Growing earnings per share by 13%** (ex-antigen), adj. basic EPS of €2.02
- **Proposed dividend** of €0.95 per share

<table>
<thead>
<tr>
<th>Outlook achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue growth</strong></td>
</tr>
<tr>
<td>2023 Outlook</td>
</tr>
<tr>
<td>Comp. revenue growth(^1) ex antigen</td>
</tr>
<tr>
<td>Comp. revenue growth(^1)</td>
</tr>
<tr>
<td><strong>Adjusted EPS</strong></td>
</tr>
<tr>
<td>2023 Outlook</td>
</tr>
<tr>
<td>Adj. basic EPS (€)</td>
</tr>
<tr>
<td>Adj. basic EPS growth ex antigen</td>
</tr>
</tbody>
</table>

\(^1\) Year-over-year on a comparable basis, excluding currency translation and portfolio effects as well as effects in line with revaluation of contract liabilities from IFRS 3 PPA
CEO update
Sustaining double-digit earnings growth by 2025 and beyond

By 2025

- **Revenue growth**\(^1\) 6-8% CAGR\(^2\)
- **Adj. EPS growth** 12-15% CAGR\(^2\)

Beyond 2025

- **Revenue growth**\(^1\) Mid to high single-digits
- **Adj. EPS growth** Double-digits

\(^1\) Comparable revenue growth excluding foreign exchange and portfolio effects
\(^2\) CAGR from 2023 to 2025
Our sources of growth

The world innovates for us
- Novel drugs
- New theranostic agents
- Robotic treatments
- More sophisticated devices

Innovating continuously
- for better diagnosis and treatment

Expanding access to care
- for billions of people

Enabling efficient operations
- to improve productivity

Secular growth
- Growing population
- Rising NCD\(^1\) burden
- Ageing population
- Expanding insurance coverage

Provider challenges
- Staff shortage
- Hospital consolidation
- Cost pressure
- Procedure growth
Our unique capabilities

Patient Twinning
Personalization of diagnosis, therapy selection and monitoring, after care and managing health

Precision Therapy
Intelligent and image guided treatment for the most threatening diseases

Digital, Data and AI
Leveraging digital, data and AI and advance providers’ operations with tech-enabled and enterprise services
Our sources of value creation

Leveraging the power of our unique, synergistic portfolio and capabilities

Winning together
Imaging, Varian, Advanced Therapies

Crystalizing full potential of growth and profitability
Transforming to win
Diagnostics

Creating value
Leveraging the power of our unique, synergistic portfolio and capabilities

- Unmatched breadth and depth of leading synergistic portfolio
- Unmatched relevance in all major disease states and key clinical departments
- Continuously expanding and leveraging of scale advantages in R&D, production, sales and service
- Leading global footprint and strong resilience
- Fast-growing revenue and backlog from multi-year Value Partnerships, leveraging unique C-Level access
- Industry-leading growth and margins from innovator premium and scale
Crystalizing full potential of growth and profitability

• Strong product portfolio in an attractive market
• Transformation program ongoing to optimize set-up, to right-size structure and to support acceleration of growth
• On track to reach €300m cost out by 2025
• Crystalizing value of three compelling subsegments:
  - Central Lab with Atellica gaining full traction; consolidating core lab footprint in one competitive offering
  - Specialty Lab with strong position; leveraging further growth and earnings potential
  - Point of Care with accelerating top- and bottom-line growth; executing to maximize potential
Raising the bar on our sustainability commitment

HEALTHCARE ACCESS

Patient impact
260 million patient touchpoints\(^1\) by 2030
Expanding to patient impact in underserved communities globally

Healthcare workforce education and training
6 million hours of training provided by 2030

RESOURCE PRESERVATION

Net zero
90% reduction in Scope 1 & 2 emissions by 2030\(^2\)
28% reduction in Scope 3 emissions by 2030, 90% by 2050\(^2\)

Circularity
Increase share of circular revenue by 2030

DIVERSE AND ENGAGED HEALTHINEERS

Diversity
30% women representation in Senior Management roles by 2025

Employee engagement
Maintain Top Quartile employee engagement score

External recognition
“Great Place To Work” in countries representing >80% of employees by 2025

Volunteering and Employee-led initiatives

Global and Regional Partnerships

---

1 Based on 90 underserved countries, classified by World Bank as low-income and lower-middle income economies, and Siemens Healthineers’ specific additions. | 2 vs. baseline 2019

Q4 FY2023
Unrestricted © Siemens Healthineers AG, 2023 l 14
We pioneer breakthroughs in healthcare.
For everyone. Everywhere. Sustainably.
CFO update
Strong finish in Q4

- Excellent equipment book-to-bill of 1.16
- Very strong revenue growth of 10.8% ex antigen with revenue growth across all segments (growth of 7.5% incl. antigen)
- Very strong growth ex antigen in Americas (13%), EMEA (14%), and Asia Pacific Japan (10%), China (-3%) temporarily held back
- Strong adj. EBIT margin at 16.7%; y-o-y up 160 bps ex antigen
- Adjusted basic EPS at €0.58; y-o-y up 3% ex antigen despite higher interest expenses and higher tax rate
- Free cash flow €557m, y-o-y up 23%

1 Year-over-year on a comparable basis, excluding currency translation and portfolio effects as well as effects in line with revaluation of contract liabilities from IFRS 3 PPA
• Excellent growth in Q4 (vs. 8% in PYQ) driven by significant growth at MI and MR¹
• Y-o-Y headwind from incentive provisions offset by FX tailwind (FX ~100 bps)
• Sequential margin improvement every quarter to a strong finish in Q4
• PYQ particular strong with catch-up effects from PYQ3

• Revenue ex-antigen continues to grow at 2%
• Margin at 2% (ex-antigen and ex-transformation costs) from stabilizing topline despite y-o-y FX headwind (~100 bps)
• Transformation costs (~€29m) offset by antigen contribution
• Antigen revenue of ~€50m (PYQ: ~€230m)

---

¹ MI: Molecular Imaging; MR: Magnetic Resonance
**Varian – very strong finish**  
**Advanced Therapies – robust finish**

### Varian (€m)

<table>
<thead>
<tr>
<th></th>
<th>Q4 FY2022</th>
<th>Q4 FY2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted revenue</td>
<td>829</td>
<td>1,017</td>
</tr>
<tr>
<td>Adj. EBIT (margin)</td>
<td>100 (12.1%)</td>
<td>190 (18.7%)</td>
</tr>
</tbody>
</table>

- **Comparable Growth**: +29.8%  
- **Margin Y-o-Y**: +660 bps

### Advanced Therapies (€m)

<table>
<thead>
<tr>
<th></th>
<th>Q4 FY2022</th>
<th>Q4 FY2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted revenue</td>
<td>578</td>
<td>564</td>
</tr>
<tr>
<td>Adj. EBIT (margin)</td>
<td>89 (15.3%)</td>
<td>99 (17.5%)</td>
</tr>
</tbody>
</table>

- **Comparable Growth**: +5.1%  
- **Margin Y-o-Y**: +220 bps

- **Excellent revenue growth with a very strong finish in Q4, more than making up for the shortfall in Q3**
- **Margin y-o-y up from strong conversion, more than compensating FX headwind (FX ~100 bps)**
- **PYQ had low conversion due to headwinds from supply-chain delays**

- **Continued growth in Q4 (vs. 6% in PYQ)**
- **Strong Q4 margin from y-o-y conversion and FX tailwind (~150 bps)**
- **Ongoing invest in Endovascular Robotics, dilution starting to decrease**
Clear priorities for continuous value creation

**Imaging, Varian, Advanced Therapies**

**Equipment book-to-bill continuously >1**
Continuing market share gains, growing equipment order backlog substantiating equipment revenues

**Recurring revenue of ~45%**
Recurring service revenues + Value Partnerships adding long-term revenues

**Expanding innovator margins**
Gross margins benefitting from pricing excellence and from operating leverage

**Diagnostics**

**Transforming business to deliver sustainable growth**
Atellica Solution and Atellica CI Analyzer newest IA/CC¹ solution in the in-vitro diagnostics market

**Recurring revenue of ~90%**
90% of revenues from recurring reagent sales

**Realizing margin potential**
Right-size cost position to industry standards

**Investing into innovation**
Industry-leading R&D invest of >€2bn² (~8 to 9% of revenue)
Capex fluctuating between 3.5% and 4.5% of revenue, near term in the upper half of range due to capacity expansions

**Highly cash-generative businesses**
Targeting Free cash to EBIT ratios of ~90% in Imaging, Varian and Advanced Therapies; Diagnostics in transition
Focus on deleveraging in FY24: Targeting leverage towards 3.0x in FY24 (from 3.7 in FY23) and 2x in FY25 and beyond
High share of recurring revenues smooths revenue growth, and ensures resilience in challenging environments

**Imaging, Varian, AT**
- Growing recurring revenues from service and software
- Value Partnerships add long-term recurring revenues

**Diagnostics**
- High share of recurring revenues from reagent revenues
- Razor-razorblade business model

**Group revenue growth**

- **Pandemic**
  - Q1: 0%
  - Q2: 5%
  - Q3: 12%
  - Q4: 10%

- **Post Pandemic**
  - Q1: 4%
  - Q2: 8%
  - Q3: 11%
  - Q4: 10%

**Notes**
- FY2020: Trough with start of pandemic in 2020
- FY2021: Pent-up deliveries in 2021
- FY2022: Tough comps for 2022 growth
- FY2023: Outgrown volatility after pandemic

1 AT: Advanced Therapies | 2 ex antigen
Equipment book-to-bill is the most meaningful indicator for future revenue growth

- Equipment book-to-bill above 1 expands order backlog – substantiating future revenue growth
- Equipment book-to-bill above 1 in every quarter – except two quarters in the pandemic
- Very strong over whole fiscal years

### Equipment book-to-bill

| Q1 FY2020 | Q2 FY2020 | Q3 FY2020 | Q4 FY2020 | Q1 FY2021 | Q2 FY2021 | Q3 FY2021 | Q4 FY2021 | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| 1.21      | 0.94      | 0.94      | 1.15      | 1.16      | 1.08      | 1.17      | 1.19      | 1.22      | 1.29      | 1.23      | 1.36      | 1.01      | 1.11      | 1.16      |

### Equipment order growth

- Revenue growth **not linked to quarterly equipment order growth**
- **Substantial volatility** of y-o-y equipment order growth in a quarter – even more drastic in a single market
- Quarterly equipment order growth is **not a meaningful indicator for future revenue growth**

1 From Q3 FY2022 onwards including Varian | 2 ex antigen

Unrestricted © Siemens Healthineers AG, 2023 | 22
### Outlook 2024

#### Siemens Healthineers

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comp. revenue growth</td>
<td>1.2%</td>
<td>4.5% to 6.5%</td>
</tr>
<tr>
<td>Comp. revenue growth, ex-antigen</td>
<td>8.3%</td>
<td>5.0% to 7.0%</td>
</tr>
<tr>
<td>Adj. basic EPS (€)</td>
<td>2.14</td>
<td>2.10 to 2.30</td>
</tr>
</tbody>
</table>

#### Main assumptions

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comp. revenue growth</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging</td>
<td>10.9%</td>
<td>6% to 8%</td>
</tr>
<tr>
<td>Diagnostics, ex antigen</td>
<td>-1.2%</td>
<td>2% to 4%</td>
</tr>
<tr>
<td>Varian</td>
<td>14.8%</td>
<td>8% to 10%</td>
</tr>
<tr>
<td>Advanced Therapies</td>
<td>7.8%</td>
<td>5% to 8%</td>
</tr>
<tr>
<td><strong>Adj. EBIT margin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging</td>
<td>21.8%</td>
<td>21.0% to 22.5%</td>
</tr>
<tr>
<td>Diagnostics, ex antigen</td>
<td>-0.8%</td>
<td>2.5% to 4.5%</td>
</tr>
<tr>
<td>Varian</td>
<td>15.1%</td>
<td>15% to 17%</td>
</tr>
<tr>
<td>Advanced Therapies</td>
<td>15.4%</td>
<td>15% to 17%</td>
</tr>
</tbody>
</table>

#### Further line items

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Items adj. EBIT (€m)</td>
<td>-210</td>
<td>-290 to -260</td>
</tr>
<tr>
<td>Financial income net (€m)</td>
<td>-207</td>
<td>-320 to -280</td>
</tr>
<tr>
<td>Tax rate (in %)</td>
<td>20.9</td>
<td>24.0 to 26.0</td>
</tr>
</tbody>
</table>

**Note:** All figures for FY2023 and FY2024 as of new adjustment definition for adjusted EBIT and adjusted EPS, for details see appendix. FY2023 with €121m antigen revenue impacting adj. basic EPS with ~€0.05, FY2024 assumes no antigen.
Sustaining double-digit earnings growth by 2025 and beyond

By 2025

Revenue growth\(^1\) 6-8% CAGR\(^2\)

Adj. EPS growth 12-15% CAGR\(^2\)

Beyond 2025

Revenue growth\(^1\) Mid to high single-digits

Adj. EPS growth Double-digits

Segment trajectories

Imaging to grow by at least mid single-digits; continued margin expansion from scale
Varian to grow by at least high single-digits; margins advancing towards Imaging-like levels
Advanced Therapies to grow by at least mid single-digits; margins returning to industry-leading levels
Diagnostics to grow by at least market rate; margins advancing to mid teens

1 Comparable revenue growth excluding foreign exchange and portfolio effects | 2 CAGR from 2023 to 2025
We pioneer breakthroughs in healthcare.
For everyone. Everywhere. Sustainably.
Free cash flow higher than in prior-year quarter; strong Q4 revenue led to increased level of OWC

Q4 FY23 Siemens Healthineers EBIT to Free Cash Flow (€m)

<table>
<thead>
<tr>
<th></th>
<th>Healthineers EBIT</th>
<th>PPA amortization</th>
<th>EBIT excl. PPA &amp; amort. of intang. excl. PPA</th>
<th>EBITDA</th>
<th>Change in OWC</th>
<th>Change in other assets &amp; liabilities</th>
<th>Add. to operating leases</th>
<th>Other</th>
<th>Operating cash flow pre tax</th>
<th>Add. to intangible assets, PPE</th>
<th>Repayment of 3rd party lease liabilities</th>
<th>FCF pre tax - Repayment of lease liabilities</th>
<th>Repayment of 3rd party lease liabilities</th>
<th>Income taxes</th>
<th>Free cash flow</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€858</td>
<td>€93</td>
<td>€952</td>
<td>€234</td>
<td>€-405</td>
<td>€168</td>
<td>€-65</td>
<td>€118</td>
<td>€1’002</td>
<td>€-241</td>
<td>€715</td>
<td>€47</td>
<td>€-204</td>
<td>€557</td>
<td></td>
</tr>
</tbody>
</table>

1 CCR for Healthineers = (Free Cash Flow pre tax - Repayment of 3rd party lease liabilities) / (Healthineers EBIT excl. PPA)
2 CCR for Segments = Free Cash Flow / EBIT

CCR¹ 0.75

CCR²

- Imaging
- Diagnostics
- Varian
- Adv. Therapies

-0.9

Underwater

Q4 FY2023

Unrestricted © Siemens Healthineers AG, 2023
**FY23 balance sheet and net debt bridge**

**Cash flow from operating activities held back by increased OWC**

---

### Net debt overview

<table>
<thead>
<tr>
<th>in €bn</th>
<th>Sep 30, 2022</th>
<th>Sep 30, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>1.4</td>
<td>1.6</td>
</tr>
<tr>
<td>Receivables from the Siemens Group from financing activities</td>
<td>0.7</td>
<td>0.6</td>
</tr>
<tr>
<td>Short-term and long-term financial debt</td>
<td>(0.7)</td>
<td>(0.6)</td>
</tr>
<tr>
<td>Liabilities to the Siemens Group from financing activities²</td>
<td>(13.5)</td>
<td>(14.8)</td>
</tr>
<tr>
<td><strong>Net debt</strong></td>
<td>(12.0)</td>
<td>(13.1)</td>
</tr>
<tr>
<td>Provisions for pensions and similar obligations</td>
<td>(0.7)</td>
<td>(0.5)</td>
</tr>
<tr>
<td><strong>Net debt (incl. pensions)</strong></td>
<td>(12.7)</td>
<td>(13.7)</td>
</tr>
</tbody>
</table>

---

### Capital structure development in FY23 (in €bn)

- **Leverage¹**: 3.0x to 3.7x
- **Net Debt**: 12.0 to 13.1
- **Pensions**: 0.7 to 0.5

---

¹ Leverage is net debt incl. pension over EBITDA rolling four quarters
² Includes fair values from derivatives

---

Q4 FY2023

Unrestricted © Siemens Healthineers AG, 2023 | 28
Loan maturity profile

Loans with Siemens Group as of Sep 30th, 2023¹ (in €m)

- Other
- EUR
- USD

<table>
<thead>
<tr>
<th>Loans with Siemens Group as of Sep 30th, 2023¹ (in €m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Notional</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>EUR</td>
</tr>
<tr>
<td>USD</td>
</tr>
<tr>
<td>EUR</td>
</tr>
</tbody>
</table>

Comments

- Total loan volume ~€13.2bn equivalent
- Average interest rate ~1.7% p.a.³

Top 10 loans ranked in € volume

¹ Unhedged loans translated to EUR according to spot rate as of Sep 30th, 2023
² USD loans addressed by SHS debt & capital restructuring resulting in synthetic EUR debt; EUR volume and interest rates are calculated with underlying hedge rates
³ Current interest rate across all maturities as of Sep 30th, 2023 is ~1.7% p.a.
⁴ Floating interest rate – in FY2024, only the hedged €834m loan (out of €2,086m) is based on a floating interest rate
## Provisions for pensions

### Q4 FY2023 Key financials – Pensions and similar obligations

<table>
<thead>
<tr>
<th>in €bn¹</th>
<th>FY2018</th>
<th>FY2019</th>
<th>FY2020</th>
<th>FY2021</th>
<th>FY2022</th>
<th>Q1 FY2023</th>
<th>Q2 FY2023</th>
<th>Q3 FY2023</th>
<th>Q4 FY2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Defined benefit obligation (DBO)</strong></td>
<td>-3.4</td>
<td>-3.8</td>
<td>-3.8</td>
<td>-4.1</td>
<td>-3.3</td>
<td>-3.2</td>
<td>-3.3</td>
<td>-3.3</td>
<td>-3.2</td>
</tr>
<tr>
<td><strong>Fair value of plan assets</strong></td>
<td>2.6</td>
<td>2.8</td>
<td>2.8</td>
<td>3.3</td>
<td>2.8</td>
<td>2.7</td>
<td>2.8</td>
<td>2.8</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>Provisions for pensions and similar obligations²</strong></td>
<td>-0.8</td>
<td>-1.0</td>
<td>-1.0</td>
<td>-0.9</td>
<td>-0.7</td>
<td>-0.6</td>
<td>-0.6</td>
<td>-0.6</td>
<td>-0.5</td>
</tr>
<tr>
<td><strong>Discount rate</strong></td>
<td>2.9%</td>
<td>1.8%</td>
<td>1.5%</td>
<td>1.7%</td>
<td>4.3%</td>
<td>4.2%</td>
<td>4.0%</td>
<td>4.1%</td>
<td>4.8%</td>
</tr>
<tr>
<td><strong>Interest Income</strong></td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Actual return on plan assets (after expenses)</strong></td>
<td>0.1</td>
<td>0.3</td>
<td>0.1</td>
<td>0.2</td>
<td>(0.6)</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
</tbody>
</table>

1. All figures are reported on a continuing basis  
2. Provisions for pensions and similar obligations does not include net defined benefit assets (Q4 FY2023: €+0.1bn) presented in the line item other assets; Defined Benefit Obligation (DBO) including other post-employment benefit plans (OPEB) of ~€-0.0bn
New definition for adjustments

To maintain consistency of comparable financial results between periods, the definition of adjusted EBIT and adjusted EPS will be modified to exclude other expenses in connection with restructuring measures within the meaning of IAS 37 starting from Oct 1st, 2023.

Based on the new adjustment definition, €152m of costs reported as transformation costs would have been adjusted in the Diagnostics segment in FY2023. Additionally, there are minor adjustments outside of the Diagnostics segment.

Adjustments as of new definition

<table>
<thead>
<tr>
<th>(in €m)</th>
<th>FY2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPA effects</td>
<td>-393</td>
</tr>
<tr>
<td>M&amp;A-related expenses</td>
<td>-37</td>
</tr>
<tr>
<td>Severance charges</td>
<td>-167</td>
</tr>
<tr>
<td>Other portfolio-related measures</td>
<td>-349</td>
</tr>
<tr>
<td>Other restructuring expenses</td>
<td></td>
</tr>
<tr>
<td>New</td>
<td>-170</td>
</tr>
<tr>
<td>Tax effect on adjustments</td>
<td>233</td>
</tr>
</tbody>
</table>

Note: Please see next page for FY2023 figures based on the new adjustment definition
1 IAS 37: International Accounting Standard – Provisions, contingent liabilities and contingent assets
Figures based on the new adjustment definition for Diagnostics and Siemens Healthineers

New adjustment definition for adjusted EBIT and adjusted EPS (effective as of Oct 1st, 2023)

<table>
<thead>
<tr>
<th>in €m</th>
<th>Q1 FY2023</th>
<th>Q2 FY2023</th>
<th>Q3 FY2023</th>
<th>Q4 FY2023</th>
<th>FY2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted EBIT</td>
<td>10</td>
<td>-33</td>
<td>6</td>
<td>52</td>
<td>35</td>
</tr>
<tr>
<td>Adjusted EBIT margin</td>
<td>0.8%</td>
<td>-3.0%</td>
<td>0.5%</td>
<td>4.3%</td>
<td>0.8%</td>
</tr>
<tr>
<td><strong>Siemens Healthineers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted EBIT</td>
<td>685</td>
<td>764</td>
<td>758</td>
<td>1,045</td>
<td>3,251</td>
</tr>
<tr>
<td>Adjusted EBIT margin</td>
<td>13.5%</td>
<td>14.3%</td>
<td>14.6%</td>
<td>17.2%</td>
<td>15.0%</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>0.50</td>
<td>0.49</td>
<td>0.55</td>
<td>0.60</td>
<td>2.14</td>
</tr>
<tr>
<td>Adjusted EPS y-o-y growth</td>
<td>-8.5%</td>
<td>-28.0%</td>
<td>27.0%</td>
<td>-9.0%</td>
<td>-7.6%</td>
</tr>
<tr>
<td>Adjusted EPS y-o-y growth (ex antigen)</td>
<td>8.2%</td>
<td>10.1%</td>
<td>69.2%</td>
<td>5.0%</td>
<td>18.8%</td>
</tr>
</tbody>
</table>
**Glossary**

**Adjusted revenue**
is defined as consolidated revenue reported in the company’s consolidated statements of income adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.

**Comparable revenue growth**
is defined as the development of adjusted revenue, respectively, net of currency translation effects, which are beyond our control, and portfolio effects, which involve business activities that are either new to our business or no longer a part of it.

**EBITDA**
is defined as income before income taxes, interest income and expenses, other financial income, net as well as amortization, depreciation & impairments.

**Adjusted EBIT (adj. EBIT) ¹**
is defined as income before income taxes, interest income and expenses and other financial income, net, adjusted for expenses for portfolio-related measures, severance charges (and from fiscal year 2024 onwards for other expenses in connection with restructuring measures within the meaning of IAS 37). In addition, centrally carried pension service and administration expenses are excluded from adjusted EBIT of the segments.

**Adjusted EBIT margin (adj. EBIT margin) ¹**
is defined as the adjusted EBIT, divided by adjusted total revenue.

**Adjusted basic earnings per share (adj. basic EPS) ¹**
is defined as basic earnings per share, adjusted for portfolio-related measures and severance charges (and from fiscal year 2024 onwards for other expenses in connection with restructuring measures within the meaning of IAS 37), net of tax.

**Free cash flow (FCF)**
comprises the cash flows from operating activities and additions to intangible assets and property, plant and equipment included in cash flows from investing activities.

**Equipment book-to-bill ratio**
is the ratio between equipment orders and equipment revenue, where equipment refers to all businesses except Diagnostics and product-based services.

---

¹ Starting in fiscal year 2024, the definition will be adapted as indicated. For more information, please refer to page 31 in this presentation.